Another of the world\u2019s top pharmaceutical companies is making Pennsylvania a part of major North American expansion plans.<\/p>\n
Johnson & Johnson said Wednesday it will build a new \u201cnext-generation\u201d cell therapy plant in Lower Gwynedd, Montgomery County.<\/p>\n
The company said the $1 billion-plus plant, operated under Johnson & Johnson\u2019s Janssen BioTech flag, will open in 2031, and will eventually create more than 500 bio-manufacturing jobs.<\/p>\n
It is the second major pharmaceutical site win for Pennsylvania in as many months, coming on the heels of Eli Lilly & Co.\u2019s announcement of a $3.5 billion plant in the Lehigh Valley in January.<\/a><\/p>\n Johnson & Johnson announced it was coming to Pennsylvania with one of a series of four new, tariff-busting plants in January.<\/p>\n Today\u2019s announcement was a reveal of the exact location.<\/p>\n Johnson & Johnson CEO Joaquin Duato, standing with Gov. Josh Shapiro, said the new plant \u201cwill advance the company\u2019s industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases…<\/p>\n \u201cThe new facility will increase our already significant footprint in the Commonwealth, adding U.S.-based jobs to manufacture cutting edge medicines for patients.\u201d<\/p>\n Immune-mediated diseases, according to the Cleveland Clinic,<\/a> occur when a person\u2019s immune system is more active than it should be. With no invaders to attack, the immune system turns on the patient\u2019s body and damages healthy tissue.<\/p>\n Autoimmune diseases are usually chronic conditions, requiring lifetime management of the disease and the symptoms it causes.<\/p>\n Wednesday\u2019s announcement is part of New Jersey-based Johnson & Johnson\u2019s previously announced plan to invest $55 billion in U.S. manufacturing, research and development, and technology through early 2029.<\/p>\n Many pharmaceutical companies are working to bring more drug manufacturing into the U.S. as part of a deal with the Trump Administration for tariff relief.<\/p>\n As another part of that deal, the company announced last month it would fully participate in TrumpRx.gov,<\/a> a direct to patient platform designed to allow millions of American patients to purchase medicines at significantly discounted rates considered comparable to pricing schemes in other developed countries.<\/p>\n \u201cOur goal is that, at the completion of our… investment plan, essentially all the advanced medicines that are used in the U.S. will be manufactured here in the U.S. And I think that\u2019s great,\u201d Duato said last month, addressing the 2026 J.P. Morgan Healthcare Conference.<\/p>\n \u201cIt\u2019s great for the country. It\u2019s great to create jobs. And it\u2019s great to create more resiliency in our supply chain.\u201d<\/p>\n